Robert B Jenkins

List of Publications by Year
in descending order

171 papers	15,697 citations	29994 54 h-index	18606 119 g-index
172 all docs	172 docs citations	172 times ranked	17976 citing authors

#	Article	IF	Citations
1	Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas. Archives of Pathology and Laboratory Medicine, 2022, 146, 547-574.	1.2	25
2	Inherited genetics of adult diffuse glioma and polygenic risk scoresâ€"a review. Neuro-Oncology Practice, 2022, 9, 259-270.	1.0	3
3	The immunogenetics of viral antigen response is associated with subtype-specific glioma risk and survival. American Journal of Human Genetics, 2022, 109, 1105-1116.	2.6	7
4	Biology and grading of pleomorphic xanthoastrocytomaâ€"what have we learned about it?. Brain Pathology, 2021, 31, 20-32.	2.1	32
5	CODEL: phase III study of RT, RTâ€‰+ TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design. Neuro-Oncology, 2021, 23, 457-467.	0.6	58
6	Functional analysis of low-grade glioma genetic variants predicts key target genes and transcription factors. Neuro-Oncology, 2021, 23, 638-649.	0.6	9
7	Non-canonical IDH Mutation Frequency in IDH1-R132H-Negative Glioblastoma Patients Older Than 54 Years. Journal of Neuropathology and Experimental Neurology, 2021, 80, 804-806.	0.9	0
8	Myeloid malignancies with 5q and 7q deletions are associated with extreme genomic complexity, biallelic TP53 variants, and very poor prognosis. Blood Cancer Journal, 2021, 11, 18.	2.8	8
9	Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. Acta Neuropathologica, 2021, 141, 945-957.	3.9	32
10	Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma. Neuro-Oncology, 2021, 23, 1547-1559.	0.6	34
11	RNA-Seq Reveals Differences in Expressed Tumor Mutation Burden in Colorectal and Endometrial Cancers with and without Defective DNA-Mismatch Repair. Journal of Molecular Diagnostics, 2021, 23, 555-564.	1.2	16
12	Generative Adversarial Networks to Synthesize Missing T1 and FLAIR MRI Sequences for Use in a Multisequence Brain Tumor Segmentation Model. Radiology, 2021, 299, 313-323.	3.6	46
13	Detailed Reanalysis of 500 Breast Cancers With Equivocal HER2 Immunohistochemistry and Borderline ERBB2 Fluorescence In Situ Hybridization Results. American Journal of Clinical Pathology, 2021, 156, 886-894.	0.4	0
14	Assessment of isochromosome 12p and 12p abnormalities in germ cell tumors using fluorescence in situ hybridization, single-nucleotide polymorphism arrays, and next-generation sequencing/mate-pair sequencing. Human Pathology, 2021, 112, 20-34.	1.1	19
15	Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC) Tj ETQq1 1 0.784314 rgBT /O Oncology, The, 2021, 22, 813-823.	5.1	132
16	Large-scale cross-cancer fine-mapping of the 5p15.33 region reveals multiple independent signals. Human Genetics and Genomics Advances, 2021, 2, 100041.	1.0	6
17	Polymorphous Low-Grade Neuroepithelial Tumor of the Young (PLNTY): Molecular Profiling Confirms Frequent MAPK Pathway Activation. Journal of Neuropathology and Experimental Neurology, 2021, 80, 821-829.	0.9	13
18	Glioma: interaction of acquired and germline genetics. Aging, 2021, 13, 19085-19087.	1.4	1

#	Article	IF	Citations
19	SeekFusion - A Clinically Validated Fusion Transcript Detection Pipeline for PCR-Based Next-Generation Sequencing of RNA. Frontiers in Genetics, 2021, 12, 739054.	1.1	9
20	HER2 Testing for Breast Cancer in the Genomics Laboratory: A Sea Change for Fluorescence In Situ Hybridization. Archives of Pathology and Laboratory Medicine, 2021, 145, 883-886.	1.2	4
21	Lack of association between modifiable exposures and glioma risk: A Mendelian randomisation analysis. Neuro-Oncology, 2020, 22, 207-215.	0.6	19
22	Glioma risk associated with extent of estimated European genetic ancestry in African Americans and Hispanics. International Journal of Cancer, 2020, 146, 739-748.	2.3	23
23	Frequency of false-positive FISH 1p/19q codeletion in adult diffuse astrocytic gliomas. Neuro-Oncology Advances, 2020, 2, vdaa109.	0.4	15
24	Development of a gene expressionâ€“based prognostic signature for IDH wild-type glioblastoma. Neuro-Oncology, 2020, 22, 1742-1756.	0.6	18
25	8q24 clear cell renal cell carcinoma germline variant is associated with VHL mutation status and clinical aggressiveness. BMC Urology, 2020, 20, 173.	0.6	1
26	Adult diffuse glioma GWAS by molecular subtype identifies variants inD2HGDHandFAM20C. Neuro-Oncology, 2020, 22, 1602-1613.	0.6	19
27	N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-stage HER2-positive breast cancer. Breast Cancer Research and Treatment, 2020, 182, 613-622.	1.1	0
28	Concomitant 1p/19q co-deletion and IDH1/2, ATRX, and TP53 mutations within a single clone of â€œdual-genotypeâ€•IDH-mutant infiltrating gliomas. Acta Neuropathologica, 2020, 139, 1105-1107.	3.9	8
29	cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathologica, 2020, 139, 603-608.	3.9	344
30	Clinical Value of Next Generation Sequencing in the Detection of Recurring Structural Rearrangements and Copy Number Abnormalities in Acute Myeloid Leukemia. Blood, 2020, 136, 21-22.	0.6	0
31	Aspirin, NSAIDs, and Glioma Risk: Original Data from the Glioma International Caseâ€“Control Study and a Meta-analysis. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 555-562.	1.1	15
32	Sex-specific gene and pathway modeling of inherited glioma risk. Neuro-Oncology, 2019, 21, 71-82.	0.6	52
33	Spinal Cord Ependymomas With MYCN Amplification Show Aggressive Clinical Behavior. Journal of Neuropathology and Experimental Neurology, 2019, 78, 791-797.	0.9	50
34	Plenty of calcification: imaging characterization of polymorphous low-grade neuroepithelial tumor of the young. Neuroradiology, 2019, 61, 1327-1332.	1.1	48
35	A fourâ€gene transcript score to predict metastaticâ€lethal progression in men treated for localized prostate cancer: Development and validation studies. Prostate, 2019, 79, 1589-1596.	1.2	8
36	Molecular profiling of long-term IDH-wildtype glioblastoma survivors. Neuro-Oncology, 2019, 21, 1458-1469.	0.6	47

#	Article	IF	Citations
37	The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. Neuro-Oncology, 2019, 21, 1498-1508.	0.6	49
38	Desmoplastic Infantile Ganglioglioma: A MAPK Pathway-Driven and Microglia/Macrophage-Rich Neuroepithelial Tumor. Journal of Neuropathology and Experimental Neurology, 2019, 78, 1011-1021.	0.9	21
39	Improved Drug Delivery to Brain Metastases by Peptide-Mediated Permeabilization of the Bloodâ€“Brain Barrier. Molecular Cancer Therapeutics, 2019, 18, 2171-2181.	1.9	17
40	Sleeping Beauty Insertional Mutagenesis Reveals Important Genetic Drivers of Central Nervous System Embryonal Tumors. Cancer Research, 2019, 79, 905-917.	0.4	33
41	The contribution of the rs55705857 G allele to familial cancer risk as estimated in the Utah population database. BMC Cancer, 2019, 19, 190.	1.1	2
42	Using germline variants to estimate glioma and subtype risks. Neuro-Oncology, 2019, 21, 451-461.	0.6	23
43	RNA sequencing identifies a novel USP9Xâ€“USP6 promoter swap gene fusion in a primary aneurysmal bone cyst. Genes Chromosomes and Cancer, 2019, 58, 589-594.	1.5	27
44	ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer. Cancer Cell, 2019, 35, 401-413.e6.	7.7	127
45	Cationic carrier peptide enhances cerebrovascular targeting of nanoparticles in Alzheimer's disease brain. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 16, 258-266.	1.7	46
46	Mate pair sequencing improves detection of genomic abnormalities in acute myeloid leukemia. European Journal of Haematology, 2019, 102, 87-96.	1.1	35
47	Transcriptome-Wide Association Study Identifies New Candidate Susceptibility Genes for Glioma. Cancer Research, 2019, 79, 2065-2071.	0.4	26
48	Glioma-related seizures in relation to histopathological subtypes: a report from the glioma international caseâ€“control study. Journal of Neurology, 2018, 265, 1432-1442.	1.8	32
49	Mendelian randomisation study of the relationship between vitamin D and risk of glioma. Scientific Reports, 2018, 8, 2339.	1.6	23
50	SVAtools for junction detection of genome-wide chromosomal rearrangements by mate-pair sequencing (MPseq). Cancer Genetics, 2018, 221, 1-18.	0.2	65
51	Impact of atopy on risk of glioma: a Mendelian randomisation study. BMC Medicine, 2018, 16, 42.	2.3	38
52	Influence of obesity-related risk factors in the aetiology of glioma. British Journal of Cancer, 2018, 118, 1020-1027.	2.9	32
53	Molecular subtyping of tumors from patients with familial glioma. Neuro-Oncology, 2018, 20, 810-817.	0.6	8
54	Gene Expression Correlates of Site-specific Metastasis Among Men With Lymph Node Positive Prostate Cancer Treated With Radical Prostatectomy: A Case Series. Urology, 2018, 112, 29-32.	0.5	1

#	Article	IF	Citations
55	Novel BRAF alteration in desmoplastic infantile ganglioglioma with response to targeted therapy. Acta Neuropathologica Communications, 2018, 6, 118.	2.4	14
56	cIMPACT-NOW update 3: recommended diagnostic criteria for â€œDiffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IVâ€. Acta Neuropathologica, 2018, 136, 805-810.	3.9	599
57	Ageâ€specific genomeâ€wide association study in glioblastoma identifies increased proportion of â€˜lower grade gliomaâ€™â€like features associated with younger age. International Journal of Cancer, 2018, 143, 2359-2366.	2.3	21
58	Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy. Clinical Cancer Research, 2018, 24, 3908-3916.	3.2	24
59	<scp>C</scp>opy number variant analysis using genomeâ€wide mateâ€pair sequencing. Genes Chromosomes and Cancer, 2018, 57, 459-470.	1.5	44
60	Sex-specific glioma genome-wide association study identifies new risk locus at 3p21.31 in females, and finds sex-differences in risk at 8q24.21. Scientific Reports, 2018, 8, 7352.	1.6	56
61	Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 1376-1383.	1.1	9
62	Development and Verification of an RNA Sequencing (RNA-Seq) Assay for the Detection of Gene Fusions in Tumors. Journal of Molecular Diagnostics, 2018, 20, 495-511.	1.2	36
63	Genetically Defined Oligodendroglioma Is Characterized by Indistinct Tumor Borders at MRI. American Journal of Neuroradiology, 2017, 38, 678-684.	1.2	63
64	Cost-effectiveness of the Decipher Genomic Classifier to Guide Individualized Decisions for Early Radiation Therapy After Prostatectomy for Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, e299-e309.	0.9	25
65	Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality. Oncogene, 2017, 36, 3417-3427.	2.6	68
66	Evaluation of a 24â€gene signature for prognosis of metastatic events and prostate cancerâ€specific mortality. BJU International, 2017, 119, 961-967.	1.3	6
67	Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathologica, 2017, 133, 1001-1016.	3.9	245
68	Management of diffuse low-grade gliomas in adults â€” use of molecular diagnostics. Nature Reviews Neurology, 2017, 13, 340-351.	4.9	95
69	IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831. Clinical Cancer Research, 2017, 23, 4203-4211.	3.2	8
70	Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors. Nature Genetics, 2017, 49, 789-794.	9.4	259
71	MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2. Cancer Research, 2017, 77, 1021-1034.	0.4	94
72	Giant Cell Ependymoma of Lateral Ventricle: Case Report, Literature Review, and Analysis of Prognostic Factors and Genetic Profile. World Neurosurgery, 2017, 108, 997.e9-997.e14.	0.7	4

#	Article	IF	Citations
73	TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup. Clinical Cancer Research, 2017, 23, 7072-7083.	3.2	87
74	Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet, The, 2017, 390, 1645-1653.	6.3	307
75	Radiogenomics to characterize regional genetic heterogeneity in glioblastoma. Neuro-Oncology, 2017, 19, 128-137.	0.6	170
76	Molecular Analysis of Low Grade Prostate Cancer Using a Genomic Classifier of Metastatic Potential. Journal of Urology, 2017, 197, 122-128.	0.2	33
77	Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery. Oncotarget, 2017, 8, 27145-27154.	0.8	55
78	OS06.1 Genome-wide association study reveals specific differences in genetic susceptibility to glioblastoma and non-glioblastoma. Neuro-Oncology, 2017, 19, iii10-iii11.	0.6	1
79	Synchronous gemistocytic astrocytoma IDH-mutant and oligodendroglioma IDH-mutant and 1p/19q-codeleted in a patient with CCDC26 polymorphism. Acta Neuropathologica, 2017, 134, 317-319.	3.9	3
80	Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance. Oncotarget, 2017, 8, 18949-18967.	0.8	47
81	Impact of RNA degradation on fusion detection by RNA-seq. BMC Genomics, 2016, 17, 814.	1.2	34
82	PPP6R3â€USP6 amplification: Novel oncogenic mechanism in malignant nodular fasciitis. Genes Chromosomes and Cancer, 2016, 55, 640-649.	1.5	43
83	AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth. Prostate, 2016, 76, 597-608.	1.2	14
84	PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active surveillance. Modern Pathology, 2016, 29, 764-771.	2.9	53
85	History of chickenpox in glioma risk: a report from the glioma international caseâ€"control study (<scp>GICC</scp>). Cancer Medicine, 2016, 5, 1352-1358.	1.3	36
86	Approaching a Scientific Consensus on the Association between Allergies and Glioma Risk: A Report from the Glioma International Case-Control Study. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 282-290.	1.1	89
87	Statistical considerations on prognostic models for glioma. Neuro-Oncology, 2016, 18, 609-623.	0.6	20
88	Understanding inherited genetic risk of adult glioma â€" a review. Neuro-Oncology Practice, 2016, 3, 10-16.	1.0	62
89	Evaluating the Clinical Impact of a Genomic Classifier in Prostate Cancer Using Individualized Decision Analysis. PLoS ONE, 2015, 10, e0116866.	1.1	11
90	Glioma Groups Based on 1p/19q,IDH, andTERTPromoter Mutations in Tumors. New England Journal of Medicine, 2015, 372, 2499-2508.	13.9	1,632

#	Article	IF	Citations
91	Restoration of Epigenetically Silenced Sulfatase 1 Expression by 5-Aza-2â€²-Deoxycytidine Sensitizes Hepatocellular Carcinoma Cells to Chemotherapy-Induced Apoptosis. Medical Epigenetics, 2015, 3, 1-18.	262.3	8
92	Clinical and genomic analysis of metastatic prostate cancer progression with a background of postoperative biochemical recurrence. BJU International, 2015, 116, 556-567.	1.3	19
93	Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial. Journal of Clinical Oncology, 2015, 33, 701-708.	0.8	171
94	Telomere maintenance and the etiology of adult glioma. Neuro-Oncology, 2015, 17, 1445-1452.	0.6	70
95	Characterization of 1577 Primary Prostate Cancers Reveals Novel Biological and Clinicopathologic Insights into Molecular Subtypes. European Urology, 2015, 68, 555-567.	0.9	125
96	A Heritable Missense Polymorphism in CDKN2A Confers Strong Risk of Childhood Acute Lymphoblastic Leukemia and Is Preferentially Selected during Clonal Evolution. Cancer Research, 2015, 75, 4884-4894.	0.4	38
97	High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer. Prostate Cancer and Prostatic Diseases, 2015, 18, 229-236.	2.0	8
98	Delineation ofMGMTHypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma. Journal of the National Cancer Institute, 2015, 108, djv369.	3.0	102
99	Combined Value of Validated Clinical and Genomic Risk Stratification Tools for Predicting Prostate Cancer Mortality in a High-risk Prostatectomy Cohort. European Urology, 2015, 67, 326-333.	0.9	178
100	Multi-Parametric MRI and Texture Analysis to Visualize Spatial Histologic Heterogeneity and Tumor Extent in Glioblastoma. PLoS ONE, 2015, 10, e0141506.	1.1	104
101	IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas. Oncotarget, 2015, 6, 30295-30305.	0.8	113
102	Longer genotypically-estimated leukocyte telomere length is associated with increased adult glioma risk. Oncotarget, 2015, 6, 42468-42477.	0.8	87
103	Peptide Carrier-Mediated Non-Covalent Delivery of Unmodified Cisplatin, Methotrexate and Other Agents via Intravenous Route to the Brain. PLoS ONE, 2014, 9, e97655.	1.1	30
104	A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy. Prostate Cancer and Prostatic Diseases, 2014, 17, 64-69.	2.0	128
105	Effective Intravenous Therapy for Neurodegenerative Disease With a Therapeutic Enzyme and a Peptide That Mediates Delivery to the Brain. Molecular Therapy, 2014, 22, 547-553.	3.7	45
106	RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1. Lancet Oncology, The, 2014, 15, 1469-1480.	5.1	226
107	The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. Nature Communications, 2014, 5, 5383.	5.8	522
108	Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation ofIDH. Journal of Clinical Oncology, 2014, 32, 783-790.	0.8	356

#	Article	IF	Citations
109	Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk. Nature Genetics, 2014, 46, 731-735.	9.4	161
110	Chromosome 8 alterations and PTEN loss in Gleason grade 3 tumor to predict the presence of unsampled grade 4 tumor: Implications for active surveillance.. Journal of Clinical Oncology, 2014, 32, 93-93.	0.8	0
111	Missense SNP rs3731249 Explains the CDKN2A Association with Childhood ALL and Shows Risk Allele Selection in Tumors with Somatic CDKN2A Alterations. Blood, 2014, 124, 129-129.	0.6	1
112	Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402. Journal of Clinical Oncology, 2013, 31, 337-343.	0.8	968
113	Genetic variants in telomerase-related genes are associated with an older age at diagnosis in glioma patients: evidence for distinct pathways of gliomagenesis. Neuro-Oncology, 2013, 15, 1041-1047.	0.6	42
114	Validation of a genomic classifier that predicts metastatic disease progression in men with high-risk pathologic features postprostatectomy.. Journal of Clinical Oncology, 2013, 31, 36-36.	0.8	1
115	A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation. Nature Genetics, 2012, 44, 1122-1125.	9.4	131
116	Clinical and genomic analysis of metastatic disease progression in a background of biochemical recurrence.. Journal of Clinical Oncology, 2012, 30, 90-90.	0.8	1
117	Validation of a genomic-clinical classifier for predicting clinical progression in high-risk prostate cancer.. Journal of Clinical Oncology, 2012, 30, 4565-4565.	0.8	0
118	Development and validation of a digital Gleason score biomarker signature for risk stratification of patients with prostate cancer.. Journal of Clinical Oncology, 2012, 30, 40-40.	0.8	0
119	A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nature Genetics, 2011, 43, 1098-1103.	9.4	251
120	Distinct germ line polymorphisms underlie glioma morphologic heterogeneity. Cancer Genetics, 2011, 204, 13-18.	0.2	77
121	Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nature Genetics, 2009, 41, 905-908.	9.4	456
122	Anaplastic Oligodendroglial Tumors: Refining the Correlation among Histopathology, 1p 19q Deletion and Clinical Outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathology, 2008, 18, 360-369.	2.1	125
123	A t(1;19)(q10;p10) Mediates the Combined Deletions of 1p and 19q and Predicts a Better Prognosis of Patients with Oligodendroglioma. Cancer Research, 2006, 66, 9852-9861.	0.4	678
124	Chromosomal imbalances detected by array comparative genomic hybridization in human oligodendrogliomas and mixed oligoastrocytomas. Genes Chromosomes and Cancer, 2005, 42, 68-77.	1.5	89
125	Reply to Palacios et al., ?ERBB2 and MYC alterations inBRCA1- andBRCA2-associated cancers?. Genes Chromosomes and Cancer, 2005, 42, 206-206.	1.5	0
126	Frequency of Clonal Evolution by FISH in Untreated, Early Stage Patients with CLL: A Prospective, Longitudinal Study with Long Clinical Follow-Up.. Blood, 2005, 106, 2098-2098.	0.6	3

#	Article	IF	Citations
127	N997B: Phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM): Updated results and correlative laboratory analysis. Journal of Clinical Oncology, 2005, 23, 1505-1505.	0.8	4
128	NCCTG phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM). Journal of Clinical Oncology, 2004, 22, 1503-1503.	0.8	5
129	Immunohistochemical detection of EGFRvIII and prognostic significance in patients with malignant glioma enrolled in NCCTG clinical trials. Journal of Clinical Oncology, 2004, 22, 1508-1508.	0.8	2
130	HER2 testing by local, central, and reference laboratories in the NCCTG N9831 Intergroup Adjuvant Trial. Journal of Clinical Oncology, 2004, 22, 567-567.	0.8	9
131	Focal HER2/neu amplified clones partially account for discordance between immunohistochemistry and fluorescence in-situ hybridization results: data from NCCTG N9831 Intergroup Adjuvant Trial. Journal of Clinical Oncology, 2004, 22, 568-568.	0.8	6
132	Immunohistochemical detection of EGFRvIII and prognostic significance in patients with malignant glioma enrolled in NCCTG clinical trials. Journal of Clinical Oncology, 2004, 22, 1508-1508.	0.8	4
133	Papillary Renal Cell Carcinoma: Analysis of Germline Mutations in the MET Proto-Oncogene in a Clinic-Based Population. Genetic Testing and Molecular Biomarkers, 2001, 5, 101-106.	1.7	33
134	Losses of Chromosomal Arms 1p and 19q in the Diagnosis of Oligodendroglioma. A Study of Paraffin-Embedded Sections. Modern Pathology, 2001, 14, 842-853.	2.9	110
135	Small Cell Architectureâ€"A Histological Equivalent of EGFR Amplification in Glioblastoma Multiforme?. Journal of Neuropathology and Experimental Neurology, 2001, 60, 1099-1104.	0.9	102
136	Glioblastoma-related gene mutations and over-expression of functional epidermal growth factor receptors in SKMG-3 glioma cells. Acta Neuropathologica, 2001, 101, 605-615.	3.9	26
137	Genetic alterations and chemotherapeutic response in human diffuse gliomas. Expert Review of Anticancer Therapy, 2001, 1, 595-605.	1.1	21
138	Alterations of Chromosome Arms 1p and 19q as Predictors of Survival in Oligodendrogliomas, Astrocytomas, and Mixed Oligoastrocytomas. Journal of Clinical Oncology, 2000, 18, 636-636.	0.8	1,027
139	Investigation of germline PTEN, p53, p16INK4A/p14ARF, and CDK4 alterations in familial glioma. , 2000, 92, 136-141.		60
140	Loss of expression of theDRR 1 gene at chromosomal segment 3p21.1 in renal cell carcinoma. , 2000, 27, 1-10.		60
141	Coamplification of prostate stem cell antigen (PSCA) andMYC in locally advanced prostate cancer. , 2000, 27, 95-103.		97
142	Mapping of the chromosome 19 q-arm glioma tumor suppressor gene using fluorescence in situ hybridization and novel microsatellite markers. Genes Chromosomes and Cancer, 2000, 29, 16-25.	1.5	13
143	Mapping of the chromosome 19 qâ€arm glioma tumor suppressor gene using fluorescence in situ hybridization and novel microsatellite markers. Genes Chromosomes and Cancer, 2000, 29, 16-25.	1.5	74
144	Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene, 1999, 18, 2343-2350.	2.6	487

#	Article	IF	Citations
145	A novel region of deletion on chromosome 6q23.3 spanning less than 500â€‰Kb in high grade invasive epithelial ovarian cancer. Oncogene, 1999, 18, 3913-3918.	2.6	32
146	Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene, 1999, 18, 4144-4152.	2.6	354
147	Frequent deletions within FRA7G at 7q31.2 in invasive epithelial ovarian cancer. , 1999, 24, 48-55.		31
148	Loss of markers linked toBRCA1 precedes loss at important cell cycle regulatory genes in epithelial ovarian cancer. , 1999, 25, 65-69.		7
149	Mutation and expression analysis of thep73 gene in prostate cancer. , 1999, 39, 94-100.		31
150	FRA7G extends over a broad region: coincidence of human endogenous retroviral sequences (HERV-H) and small polydispersed circular DNAs (spcDNA) and fragile sites. Oncogene, 1998, 16, 2311-2319.	2.6	68
151	Frequent homozygous deletions in the FRA3B region in tumor cell lines still leave the FHIT exons intact. Oncogene, 1998, 16, 635-642.	2.6	28
152	Independent origin of multiple foci of prostatic intraepithelial neoplasia. Cancer, 1998, 83, 1995-2002.	2.0	174
153	Familial chordoma with probable autosomal dominant inheritance. , 1998, 75, 335-336.		37
154	Prognostic significance of allelic imbalance of chromosome arms 7q, 8p, 16q, and 18q in stage T3N0M0 prostate cancer. Genes Chromosomes and Cancer, 1998, 21, 131-143.	1.5	76
155	Fish mapping of YAC clones at human chromosomal band 7q31.2: Identification of YACS spanning FRA7G within the common region of LOH in breast and prostate cancer. , 1998, 21, 152-159.		66
156	Prognostic significance of allelic imbalance of chromosome arms 7q, 8p, 16q, and 18q in stage T3N0M0 prostate cancer. , 1998, 21, 131.		3
157	A molecular cytogenetic analysis of 7q31 in prostate cancer. Cancer Research, 1998, 58, 759-66.	0.4	63
158	Chromosomal Anomalies in Stage D1 Prostate Adenocarcinoma Primary Tumors and Lymph Node Metastases Detected by Fluorescence in Situ Hybridization. Journal of Urology, 1997, 157, 223-227.	0.2	49
159	Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Research, 1997, 57, 524-31.	0.4	341
160	Application of fluorescent in situ hybridization with X and Y chromosome specific probes to buccal smear analysis. , 1996, 66, 187-192.		19
161	Cytogenetic analysis of aggressive meningiomas: Possible diagnostic and prognostic implications. , 1996, 77, 2567-2573.		61
162	Uniparental disomy in congenital disorders: A prospective study. American Journal of Medical Genetics Part A, 1995, 58, 143-146.	2.4	16

#	Article	IF	Citations
163	CYTOGENETIC ANALYSIS OF PROSTATE CARCINOMA BY FLUORESCENCE IN SITU HYBRIDIZATION. International Journal of Urology, 1995, 2, 215-223.	0.5	3
164	Detection of Trisomy 12 by FISH in Untreated B -Chronic Lymphocytic Leukemia: Correlation with Stage and CD20 Antigen Expression Intensity. Leukemia and Lymphoma, 1994, 14, 447-451.	0.6	20
165	Prognostic factors in gliomas. A multivariate analysis of clinical, pathologic, flow cytometric, cytogenetic, and molecular markers. Cancer, 1994, 74, 920-927.	2.0	79
166	Refractory Thrombocytopenia: A Myelodysplastic Syndrome That May Mimic Immune Thrombocytopenic Purpura. American Journal of Clinical Pathology, 1992, 98, 502-510.	0.4	50
167	Cytogenetic and loss of heterozygosity studies in ependymomas, pilocytic astrocytomas, and oligodendrogliomas. Genes Chromosomes and Cancer, 1992, 5, 348-356.	1.5	170
168	Correlation of cytogenetic analysis and loss of heterozygosity studies in human diffuse astrocytomas and mixed oligo-astrocytomas. Genes Chromosomes and Cancer, 1992, 5, 357-374.	1.5	108
169	Prognostic value of cytogenetic analysis in human cerebral astrocytomas. Annals of Neurology, 1992, 31, 534-542.	2.8	45
170	Fluorescence in situ hybridization: a sensitive method for trisomy 8 detection in bone marrow specimens. Blood, 1992, 79, 3307-15.	0.6	92
171	TP53 Gene Mutations and 17p Deletions in Human Astrocytomas. Genes Chromosomes and Cancer, 1991, 3, 323-331.	1.5	127